Story · Medicine & Biotech

Next-Generation Oral SERD Approved for Breast Cancer

1 outlet · first reported by MedPage Today on

(MedPage Today) -- The FDA approved the next-generation oral selective estrogen receptor degrader (SERD) giredestrant (Wilserdly) in combination with everolimus for previously treated estrogen receptor (ER)-positive, HER2-negative, ESR1-mutated... (MedPage Today)

Coverage, in order

  1. Next-Generation Oral SERD Approved for Breast Cancer

    (MedPage Today) -- The FDA approved the next-generation oral selective estrogen receptor degrader (SERD) giredestrant (Wilserdly) in combination with everolimus for previously treated estrogen receptor (ER)-positive, HER2-negative, ESR1-mutated...

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.